Hillstream BioPharma, Inc. (HILS) Bundle
Curious who's buying into Hillstream BioPharma, Inc. (HILS) and why? Right now the stock sits at $2.40 (change $0.01, 0.00%) after opening at $2.46 with an intraday high/low of $2.49/$2.33 and volume of 391,600 as of Monday, December 15, 17:15:00 PST; yet beneath these quotes lie compelling ownership and financial signals - BlackRock (9.7% / 1,500,000 shares) and Vanguard (8.5% / 1,320,000 shares) anchor major stakes while total institutional ownership is only 13.36%, a low figure that mirrors Hillstream's early-stage profile; insiders have been buying (CEO Sireesh Appajosyula bought 61,496 shares at $1.45 on June 20, 2025; Director Sanam Parikh bought 1,000 shares the same day; Gravitas Capital added 337,838 shares at $1.48), even as the company reports a net loss of -$8.47M, trailing twelve-month EPS of -$0.72 and a P/E of -0.53 (Nov 3, 2025), market cap roughly $4.057M and enterprise value of -$2.453M - and with the stock down 38.8% since the start of 2025 (from $2.06 to $1.26), the mix of significant institutional names, insider conviction, a ferroptosis-driven oncology pipeline, and stark financials makes Hillstream a polarizing bet worth a closer look; read on to see who's positioning for upside and why their moves matter.
Hillstream BioPharma, Inc. (HILS) - Who Invests in Hillstream BioPharma, Inc. (HILS) and Why?
Hillstream BioPharma, Inc. (HILS) trades in the U.S. equity market. Key intraday market facts provide a snapshot of current trading activity and liquidity that shape investor behavior.| Metric | Value |
|---|---|
| Current Price | $2.40 |
| Change (from previous close) | $0.01 (0.00%) |
| Open (latest) | $2.46 |
| Intraday High | $2.49 |
| Intraday Low | $2.33 |
| Intraday Volume | 391,600 |
| Latest Trade Time | Monday, December 15, 17:15:00 PST |
- Retail investors - attracted by low absolute share price, speculative upside, and news-driven catalysts.
- Short-term traders/day traders - target intraday volatility (high/low range $2.33-$2.49) and volume spikes (391,600) to scalp moves.
- Biotech-focused retail and accredited investors - invest based on clinical pipeline updates, licensing deals, or perceived undervaluation relative to peer therapeutics.
- Longer-term speculative investors - willing to hold through regulatory milestones or partnership announcements; motivated by potential binary outcomes typical in small-cap biotech.
- Price action and liquidity: Current price $2.40 with intraday spread shows tradability for smaller accounts and active traders.
- Catalyst dependency: Clinical trial readouts, regulatory filings, or licensing/partnership news can produce sharp re-rates.
- Risk/reward profile: Low market-cap profile often implies higher upside potential if development milestones are met, appealing to risk-tolerant investors.
- Technical patterns and momentum: Traders monitor intraday volume (391,600) and recent highs/lows for breakout or breakdown setups.
- Intraday/Short-term: Focus on price momentum between $2.33-$2.49 and volume surges; trade frequency is high given sub-$5 share price.
- Medium-term (weeks-months): Position around corporate updates; sensitivity to press releases and sector news.
- Long-term: Evaluate pipeline progress, cash runway, and strategic partnerships; less sensitive to daily 1-2% moves.
| Indicator | Why It Matters |
|---|---|
| Intraday Volume (391,600) | Liquidity gauge - higher volume supports entry/exit without large spreads. |
| Price Range ($2.33-$2.49) | Volatility window used for stop placement and profit targets. |
| Recent Open ($2.46) | Reference for gap analysis and intraday bias. |
| Latest Trade Time | Timestamp for last market activity: Monday, December 15, 17:15:00 PST. |
- Pipeline potential and milestone-driven re-rates typical for small-cap biotech names.
- Speculative retail appetite for low-priced shares with binary upside events.
- Trading-focused capital leveraging intraday liquidity and volatility metrics.
Institutional Ownership and Major Shareholders of Hillstream BioPharma, Inc. (HILS)
Hillstream BioPharma, Inc. (HILS) attracts a mix of institutional and high-risk-tolerant investors drawn to its novel ferroptosis-focused oncology platform and early-stage immuno-oncology biologics. Institutional backers provide scale and credibility, while insider buying and a concentrated shareholder base influence market sentiment.- Key institutional holders: BlackRock, Inc. (~9.7%; 1,500,000 shares) and Vanguard Group, Inc. (~8.5%; 1,320,000 shares).
- Investor rationale: exposure to an emerging anti-cancer mechanism (ferroptosis) and participation in potential upside from an early-stage pipeline.
- Risk profile: low current revenues and recurring net losses typical of pre-commercial biotech can deter conservative investors while attracting those seeking high-reward opportunities.
- Insider signals: recent purchases by CEO Sireesh Appajosyula and Director Sanam Parikh have been noted by the market as a positive vote-of-confidence.
| Shareholder | Approx. Shares | Approx. Ownership (%) | Investor Type | Notes |
|---|---|---|---|---|
| BlackRock, Inc. | 1,500,000 | 9.7% | Institutional | Large asset manager; strategic passive+active exposure to biotech |
| Vanguard Group, Inc. | 1,320,000 | 8.5% | Institutional | Index and mutual fund ownership; long-term passive exposure |
| Insiders (selected recent buyers) | N/A | N/A | Management / Board | Recent purchases by CEO Sireesh Appajosyula and Director Sanam Parikh |
| Other institutional & retail holders | N/A | N/A | Mixed | Likely concentrated given relatively low market cap and early-stage status |
- Why institutions might allocate to HILS:
- Strategic exposure to ferroptosis - an emerging area with potential to address drug-resistant cancers.
- Potential for significant valuation upside if clinical proof-of-concept milestones are met.
- Complementary fit within diversified biotech or thematic oncology strategies.
- Why some investors stay away:
- Ongoing net losses and lack of revenue consistent with pre-revenue biotech-heightened dilution and clinical risk.
- Smaller float and market cap can increase volatility and liquidity risk.
Hillstream BioPharma, Inc. (HILS) Key Investors and Their Impact on Hillstream BioPharma, Inc. (HILS)
Institutional ownership in Hillstream BioPharma, Inc. (HILS) is modest: institutions collectively hold approximately 13.36% of the company as of the latest filings, a level that reflects limited but notable participation given Hillstream's early-stage profile and the risk characteristics of small-cap biotech.- Top institutional holder by reported shares: XTX Topco Ltd - 0.148% (17,442 shares) as of March 31, 2024.
- Other notable quantitative positions include Renaissance Technologies Corp. - 0.116% (13,700 shares); Two Sigma Advisers, LLC - 0.108% (12,700 shares); Two Sigma Investments LLC - 0.088% (10,417 shares).
- Combined ownership of the top 24 institutional holders totals roughly 0.56% (66,000 shares), indicating very concentrated small positions across holders.
| Institution | Ownership % | Shares | Reporting Date |
|---|---|---|---|
| XTX Topco Ltd | 0.148% | 17,442 | Mar 31, 2024 |
| Renaissance Technologies Corp. | 0.116% | 13,700 | Mar 31, 2024 |
| Two Sigma Advisers, LLC | 0.108% | 12,700 | Mar 31, 2024 |
| Two Sigma Investments LLC | 0.088% | 10,417 | Mar 31, 2024 |
| Top 24 Institutional Holders (combined) | 0.56% | 66,000 | Mar 31, 2024 |
| All Institutional Holders (aggregate) | 13.36% | - | Latest filings |
- Drivers attracting the current institutional cohort: quantitative strategies, small-cap funds willing to trade low-liquidity tickers, and hedge funds seeking event-driven upside.
- Constraints limiting deeper institutional uptake: early-stage pipeline, recurring financial losses, limited liquidity, and elevated clinical/operational risk.
Hillstream BioPharma, Inc. (HILS) - Market Impact and Investor Sentiment
Hillstream BioPharma, Inc. (HILS) shows concentrated institutional ownership and recent insider and activist buying that together shape market perception and potential governance outcomes. Large holdings by global asset managers provide stability but also the potential for shareholder-driven pressure on strategy; recent insider purchases and a sizable position increase by an activist-style investor suggest growing confidence and/or a push for value realization.- BlackRock, Inc.: 9.7% stake - a significant institutional position capable of influencing governance votes and long-term strategy alignment.
- Vanguard Group, Inc.: 8.5% stake - another major passive/active investor that contributes to quorum and policy outcomes on compensation, board composition, and capital allocation.
- CEO Sireesh Appajosyula: purchased 61,496 shares on June 20, 2025 at $1.45 per share (+24.85% ownership change) - a strong insider signal of confidence in near- to mid-term prospects.
- Director Sanam Parikh: purchased 1,000 shares on June 20, 2025 at $1.45 per share (+36.1% ownership change) - director-level alignment with management.
- Gravitas Capital LP: purchased 337,838 shares on June 20, 2025 at $1.48 per share (+31.57% ownership change) - a material accumulation indicating activist or strategic investment intent.
| Investor | Holding (% or shares) | Recent Activity | Transaction Date | Price |
|---|---|---|---|---|
| BlackRock, Inc. | 9.7% | Position reported as major institutional holding | Most recent filing | - |
| Vanguard Group, Inc. | 8.5% | Position reported as major institutional holding | Most recent filing | - |
| Gravitas Capital LP | Increase of 31.57% (337,838 shares) | Open-market purchase - substantial accumulation | June 20, 2025 | $1.48 |
| Sireesh Appajosyula (CEO) | Holding increased 24.85% (61,496 shares) | Insider buy - signals confidence | June 20, 2025 | $1.45 |
| Sanam Parikh (Director) | Holding increased 36.1% (1,000 shares) | Director buy - alignment with management | June 20, 2025 | $1.45 |
Hillstream BioPharma, Inc. (HILS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.